COMMD5

COMMD5 (HCaRG) is an intracellular adaptor protein that couples endosomal trafficking to growth-factor receptor regulation and renal epithelial homeostasis (PMID:30021164). Mechanistically, its N-terminal domain binds the endosomal GTPase Rab5 while its C-terminal COMMD domain engages cytoskeletal scaffolding, enabling long-range endosomal transport, vesicle scission into sorting endosomes, and EGFR recycling; loss of COMMD5 reorganizes the actin and microtubule networks (PMID:30021164). Consistent with a role in restraining receptor signaling, COMMD5 drives dephosphorylation of ErbB2 and promoter methylation–dependent silencing of EGFR and ErbB3, inactivating downstream ERK, AKT, and mTOR signaling (PMID:29050225). At the cellular level it imposes G2/M arrest with p53-independent upregulation of p21 and downregulation of p27, and promotes a differentiated epithelial phenotype (PMID:12620924, PMID:24515317). In the kidney, COMMD5 accelerates re-differentiation and repair of proximal tubular epithelium after ischemia/reperfusion injury and protects tubular cells from cisplatin-induced oxidative stress by sustaining autophagy flux and limiting JNK/caspase-3–dependent apoptosis (PMID:21921141, PMID:39298552). An extracellular form of COMMD5 additionally induces ANP and eNOS in endothelial cells to promote endothelium-dependent vasodilation (PMID:36804542).

1. 2000 Medium

   Established COMMD5/HCaRG as a nuclear protein that restrains cell proliferation, framing it as a candidate growth regulator.

   Evidence Nuclear fractionation/immunostaining and overexpression proliferation assays in HEK293 cells

   PMID:10918053

   Open questions at the time

   • No molecular partner or mechanism for proliferation control identified
   • Functional domains assigned by sequence only, not validated
2. 2002 Medium

   Linked the anti-proliferative effect to a defined cell-cycle checkpoint by showing G2/M arrest with p21 up- and p27 downregulation and an epithelial differentiation program.

   Evidence Stable transfection with flow cytometry, Western blot, and differentiation/junction readouts in renal epithelial cells

   PMID:12620924

   Open questions at the time

   • Did not establish how COMMD5 transactivates p21
   • Mechanism connecting cell-cycle arrest to differentiation unresolved
3. 2005 Medium

   Connected COMMD5 to growth-factor signaling by showing it drives an autocrine TGF-alpha/EGFR loop that promotes migration.

   Evidence Conditioned-medium transfer with EGFR pathway blockade, microarray, and migration assays in HEK293/MDCK-C7

   PMID:16033922

   Open questions at the time

   • Direct molecular link between COMMD5 and TGF-alpha induction not defined
   • Receptor-level effects only partially blocked
4. 2011 Medium

   Demonstrated physiological relevance in vivo by showing COMMD5 overexpression accelerates tubular re-differentiation and repair after ischemic injury.

   Evidence Transgenic mouse ischemia/reperfusion model with E-cadherin, vimentin, Ki67 and macrophage readouts

   PMID:21921141

   Open questions at the time

   • Molecular mechanism of accelerated re-differentiation not dissected
   • Single transgenic gain-of-function model
5. 2014 Low

   Specified that COMMD5-driven p21 induction operates through a p53-independent pathway during repair.

   Evidence p21 promoter assays and transgenic ischemia/reperfusion model

   PMID:24515317

   Open questions at the time

   • Reported in a review/summary with limited methodological detail
   • p53-independent effector linking COMMD5 to p21 unidentified
6. 2017 Medium

   Revealed COMMD5 as a suppressor of ErbB receptor signaling through ErbB2 dephosphorylation and epigenetic silencing of EGFR/ErbB3.

   Evidence Overexpression in RCC cells and homograft model with phospho-Western, methylation assays, and tumor measurement

   PMID:29050225

   Open questions at the time

   • Phosphatase and methyltransferase machinery recruited by COMMD5 not identified
   • Single lab
7. 2018 High

   Defined the core molecular mechanism: COMMD5 is a bipartite adaptor linking Rab5-positive endosomes to the cytoskeleton, governing long-range trafficking and EGFR recycling.

   Evidence Reciprocal domain-mapping pulldowns, live-cell trafficking imaging, EGFR recycling and siRNA cytoskeletal imaging

   PMID:30021164

   Open questions at the time

   • Specific cytoskeletal scaffolding partner(s) of the COMMD domain not fully named
   • Link between endosomal adaptor function and nuclear/cell-cycle roles unresolved
8. 2023 Medium

   Uncovered an extracellular, endothelium-dependent vasodilatory activity of COMMD5 acting through ANP and eNOS.

   Evidence Ex vivo vascular ring assays with denuded controls and HUVEC siRNA/stimulation with ANP/eNOS readouts

   PMID:36804542

   Open questions at the time

   • Receptor or surface mechanism for extracellular COMMD5 unknown
   • Relationship between intracellular adaptor role and secreted activity unclear
9. 2024 Medium

   Showed COMMD5 protects tubular epithelium from oxidative injury by sustaining autophagy flux and suppressing JNK/caspase-3 apoptosis.

   Evidence PT-specific transgenic mouse cisplatin model plus TEC siRNA with ROS, mitochondrial, autophagy and apoptosis readouts

   PMID:39298552

   Open questions at the time

   • Mechanism by which COMMD5 enhances autophagy flux not defined
   • Direct effector linking COMMD5 to JNK regulation unknown

• How the endosomal/cytoskeletal adaptor function mechanistically integrates with the nuclear cell-cycle, epigenetic ErbB-silencing, and extracellular vasodilatory roles remains unresolved.
• No unifying mechanism connecting trafficking, transcriptional, and secreted activities
• Cytoskeletal binding partner and putative phosphatase/methyltransferase effectors unidentified
• No structural model of the bipartite domain architecture